Catalyst Pharmaceuticals IncCPRX
ASignal's systematic analysis rates CPRX as Bullish.
Reflects the latest available analysis · analyzed Aug 29, 2026
The case on CPRX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong profitability with operating margin of 49.02%
- Exceptional return on equity at 24.50%
- High gross margin of 84.04% indicating pricing power
- Net cash position with debt-to-equity ratio of 0.00x
- Current ratio of 7.10x indicating strong liquidity
- Low revenue growth at 5.60% year-over-year
- Limited Reddit retail interest with zero mentions
- PEG ratio not available due to uncertain growth visibility
- Forward P/E of 9.90x may reflect limited future earnings expectations
See the full verdict on CPRX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CPRX
Most investors never get a second opinion, let alone several. ASignal runs CPRX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.